Multiple Myeloma | Specialty

The OncLive Multiple Myeloma condition center page is a comprehensive resource for clinical news and expert insights on multiple myeloma and how to treat patients with monoclonal antibodies, proteasome inhibitors, bispecific T-cell engagers, immunomodulatory agents, CAR T-cell therapy, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in multiple myeloma.

Dr Siegel on the Use of Carfilzomib/Iberdomide/Dexamethasone Therapy in Multiple Myeloma

January 30th 2024

David Samuel Dicapua Siegel, MD, discusses the potential use of carfilzomib, iberdomide, and dexamethasone in newly diagnosed multiple myeloma.

BCMA-Targeted CAR-T Therapies in Development and Future Perspective

January 30th 2024

Dr. Raje and Dr. Abonour provide an insightful reflections on unmet needs and future perspectives in Relapsed/Refractory Multiple Myeloma (R/R MM), offering a glimpse into the evolving landscape of myeloma care.

Optimizing BCMA-Targeted CAR-T Therapies: Patient Selection, Clinical Impact, and Treatment Sequencing

January 30th 2024

Experts delve into the optimal positioning of BCMA-targeted CAR-T therapies in the treatment plan for Relapsed/Refractory Multiple Myeloma (R/R MM), providing valuable perspectives on strategic considerations in myeloma care.

Updates on BCMA-Targeting Bispecifics in MM

January 29th 2024

An expert panel reviews recent updates on BCMA-targeting bispecific antibodies in multiple myeloma.

Potential Role for CAR T-Cell Therapy in MM at Early Relapse

January 29th 2024

Krina Patel, MD, reviews data from the CARTITUDE-4 and KarMMa-3 studies and shares perspectives on a potential role for CAR T-cell therapy at early relapse.

Idecabtagene Vicleucel Approaches EU Approval in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma

January 26th 2024

The EMA's CHMP has recommended the approval of idecabtagene vicleucel in patients with multiple myeloma who received at least 2 prior therapies.

Dr Di Meo on the Potential Efficacy of LILRB4-Targeted CAR T-Cell Therapy in Multiple Myeloma

January 25th 2024

Francesco Di Meo, PhD, discusses the potential efficacy of CAR T-cells targeting the immunoreceptor LILRB4 in multiple myeloma.

Dr Siegel on the Importance of Real-World Data in Patients With Multiple Myeloma

January 24th 2024

David Samuel Dicapua Siegel, MD, emphasizes the importance of real-world evidence when treating patients with relapsed/refractory multiple myeloma.

CIBMTR Registry and CARTITUDE-2: Trial of Cilta-Cel in Patients with MM

January 23rd 2024

Dr. Abonour and Dr. Raje provide an overview of the results that were presented at ASH 2023 of the CIBMTR registry and CARTITUDE-2 trial which was the study of ciltacabtagene autoleucel (cilta-cel) in patients with MM and 1-3 prior lines of therapy (Cohort A) and with early relapse after first line treatment (cohort B).

KarMMA-3: Trial of Ide-Cel in Patients with Triple Class Exposed R/R MM

January 23rd 2024

Experts discuss the recent data presented at ASH 2023 from the KarMMA-3 trial in which ide-cel vs standard of care was studied in triple class exposed R/R MM patients.

Dr Dima on the Implications of a Real-World Analysis of Teclistamab in Multiple Myeloma

January 23rd 2024

Danai Dima, MD, discusses the implications of real-world data derived from the MajesTEC-1 trial in pretreated patients with multiple myeloma.

Treatment of Multiple Myeloma at Early Relapse

January 22nd 2024

A panel of expert hematologic-oncologists offer insights on how they treat patients with multiple myeloma at early relapse.

The Evolving Treatment Paradigm for Transplant Ineligible MM

January 22nd 2024

The expert panel discusses how the standard of care for transplant-ineligible NDMM has evolved and reviews recent updates in this space.

Lonial Reviews 2023 Highlights for Multiple Myeloma, Forecasts 2024 Research Interests

January 16th 2024

Sagar Lonial, MD, FACP, details agents of interest outside CAR T-cell therapies in multiple myeloma, including elranatamab and talquetamab.

Understanding the Role of BCMA-Targeted CAR-T Therapies in R/R MM

January 16th 2024

Noopur Raje, MD discusses the rationale for utilizing BCMA-targeted CAR-T cell therapy in myeloma patients and uncover the similarities and differences when compared to BCMA bispecific.

Evolving Treatment Landscape of Relapsed/Refractory Multiple Myeloma

January 16th 2024

Rafat Abonour, MD briefly summarizes the current treatment landscape for Relapsed/Refractory Multiple Myeloma (R/R MM) and discusses the diverse strategies and advancements in managing this complex disease.

Dr Ailawadhi on Non-BCMA CAR T-Cell Therapies Under Investigation in Multiple Myeloma

January 15th 2024

Sikander Ailawadhi, MD, discusses non-BCMA CAR T-cell therapies currently under investigation in multiple myeloma.

Role of Transplant and MRD in Newly Diagnosed MM

January 15th 2024

Amrita Krishnan, MD, and Saad Z. Usmani, MD, MBA, FACP, offer their perspectives on the role of stem cell transplant and MRD testing in patients with newly diagnosed multiple myeloma.

Advances in the Treatment of High-Risk MM

January 15th 2024

Clinical insights on the definition of high-risk multiple myeloma and the treatment of patients with high risk disease, including how the results from the IsKia trial might impact practice.

Highlights from ASH 2023 in Transplant-Eligible NDMM

January 15th 2024

Experts in multiple myeloma discuss highlights from the ASH 2023 meeting around transplant-eligible NDMM with particular focus on the PERSEUS and GRIFFIN trials and the clinical implications of the results of these studies.